May 14, 2018 / 8:23 PM / 6 months ago

BRIEF-Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial

May 14 (Reuters) - Chiasma Inc:

* CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL

* CHIASMA - FOURTH, FIFTH SECONDARY ENDPOINTS IN PHASE 3 TRIAL NOW BEEN REDEFINED TO DESCRIPTIVE STATISTICS MEASURED WITHIN EACH TREATMENT GROUP

* CHIASMA INC - UNDER SPA AGREEMENT MODIFICATION FOR CHIASMA OPTIMAL PHASE 3 TRIAL, BETWEEN-ARM COMPARISONS OF 2 DESCRIPTIVE MEASURES WILL NOT BE MADE

* CHIASMA INC - FDA INDICATED IT PLANS TO CONSIDER SECONDARY ENDPOINTS IN ITS EVALUATION OF TOTALITY OF EVIDENCE OF ORAL OCTREOTIDE’S TREATMENT EFFECT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below